These findings suggest that ATR inhibitors may be particularly effective in non-small cell lung cancer and selected ovarian cancer subgroups, but further biomarker-driven randomized trials are required to confirm their clinical value and optimize patient selection. This evidence concerns the gene ATR and ovarian cancer.